Senzime AB (publ)
SEZI
Rang in aandelen
#25302
Senzime AB (publ) is a medical technology firm specializing in the creation and... Senzime AB (publ) is a medical technology firm specializing in the creation and distribution of advanced patient monitoring solutions. These systems are designed to oversee patients undergoing anesthesia across various global markets, including Europe, Oceania, Asia, Canada, and the United States. Among its primary offerings is the TetraGraph, a sophisticated monitor designed to assess and display muscle function in surgical patients administered neuromuscular blocking agents, by stimulating, measuring, and analyzing responses. This system is complemented by the TetraSens electrode array, featuring two proximal stimulating electrodes for precise recording and reference. For data management, TetraConnect serves as a portal, allowing clinicians to conveniently access, view, and export TetraGraph data records in PDF or Excel formats. Furthermore, TetraGraph Device Connectivity facilitates the transfer of data from the TetraGraph Monitor to other patient monitoring systems, while the TetraGraph Philips Interface specifically enables the transmission of critical neuromuscular monitoring parameters—such as TOFC, TOFR, PTC, and TOF bars—to Philips patient monitors, with readings visible on the Philips Intellivue Monitor. Senzime is also actively developing the CliniSenz Analyzer, intended for continuous postoperative patient monitoring within hospital settings. Another innovation in its pipeline is the Onzurf Probe, a sterile, CE-marked single-use device leveraging micro-dialysis technology for continuous sampling from gastrointestinal organs, including the esophagus, stomach, and liver. The company maintains a strategic licensing and connectivity partnership with Masimo. This collaboration focuses on developing and commercializing the TetraGraph Smart Cable Module, designed to integrate seamlessly with Masimo's Root monitoring system and their digital hubs, thereby enabling interaction with hospital clinical information systems and electronic health records. Established in 1999, Senzime AB (publ) operates from its headquarters in Uppsala, Sweden.
Aandeelprijs
$0.30771569
Marktkapitalisatie
$48.38M
Verandering (1 dag)
-3.16%
Verandering (1 jaar)
-52.66%
Land
SE
Handel Senzime AB (publ) (SEZI)
Categorie
Healthcare
Dividendrendementgeschiedenis voor Senzime AB (publ) (SEZI)
Het dividendrendement (TTM) van Senzime AB (publ) (aandelsymbool: SEZI) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Senzime AB (publ) (SEZI) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
| Jaar | Dividendrendement | Wijzigen |
|---|---|---|
| Niet genoeg gegevens voor de verstrekte datums. | ||
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
| Bedrijf | Dividendrendement | Land |
|---|---|---|
| 2.45% |
US
|
|
| 3.69% |
IE
|
|
| 1.25% |
US
|
|
| 0.00% |
US
|
|
| 0.00% |
DE
|
